Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › uveitis

Uveitis

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for uveitis

29 trials tracked for uveitis: 14 in phase 3 or 4 and 10 with published results. The most-cited published study has 653 citations.

29Trials tracked
14Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 4 Phase 3 10 Phase 2 9 Phase 1 3 Other / NA 3
  1. Phase 3 Efficacy and Safety of Adalimumab in Patients With Active Uveitis Completed · 653 cited
  2. Phase 3 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed · 508 cited
  3. Phase 3 PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial Completed · 204 cited
  4. Phase 3 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Completed · 58 cited
  5. Phase 4 Adalimumab in JIA-associated Uveitis Stopping Trial Completed · 23 cited
  6. Phase 3 Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial Completed · 22 cited
Show 23 more trials
  1. Phase 3 Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Completed · 22 cited
  2. Phase 3 Methotrexate and Mycophenolate Mofetil for UVEITIS Completed · 18 cited
  3. Phase 3 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Completed · 18 cited
  4. Phase 3 Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Completed · 8 cited
  5. Phase 4 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed
  6. Phase 4 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed
  7. Phase 4 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed
  8. Phase 3 First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial Completed
  9. Phase 2 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed
  10. Phase 2 Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis Completed
  11. Phase 2 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Completed
  12. Phase 2 Lucentis for Inflammatory Macular Edema Trial Completed
  13. Phase 2 Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis Completed
  14. Phase 2 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed
  15. Phase 2 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Completed
  16. Phase 2 Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis Completed
  17. Phase 2 Abatacept in the Treatment of Uveitis Completed
  18. Phase 1 Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis Completed
  19. Phase 1 Sirolimus as Therapeutic Approach to Uveitis Completed
  20. Phase 1 Efalizumab to Treat Uveitis Completed
  21. N/A Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications Completed
  22. N/A Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema Completed
  23. N/A MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301 Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis of uveitis subtypes in European tertiary centers
Ophthalmology Meta-analysis
Systematic review and meta-analysis of uveitis subtypes in European tertiary centers European data show most adult uveitis cases are anterior or non-infectious
This systematic review and meta-analysis of 30 471 patients from European tertiary centers found that anterior uveitis is the most common su…
A large review of 30,471 patients found that over half of uveitis cases were anterior and nearly half were non-infectious across Europe.
May 1, 2026
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis
Pediatrics Meta-analysis
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis Combination therapy reduces relapse risk in children with eye inflammation from arthritis
This systematic review and meta-analysis of RCTs evaluated adalimumab plus methotrexate in children with juvenile idiopathic arthritis-assoc…
Combining adalimumab with methotrexate lowers relapse risk and helps reduce steroid use in children with arthritis-related eye inflammation.
May 1, 2026
Systematic review links gut dysbiosis to uveitis pathogenesis
Ophthalmology Sys. Review
Systematic review links gut dysbiosis to uveitis pathogenesis Gut health may influence eye inflammation in uveitis
This systematic review summarizes evidence on gut microbiota modulation for uveitis and inflammatory ocular diseases.
A review links gut bacteria imbalance to uveitis, suggesting eye inflammation may be tied to what's happening in your digestive system.
Frontiers Apr 23, 2026
Baricitinib showed limited efficacy in pediatric JIA-uveitis patients refractory to methotrexate or biologics at week 24
Drug Pipeline RCT
Baricitinib showed limited efficacy in pediatric JIA-uveitis patients refractory to methotrexate or biologics at week 24 New Hope for Kids with Stubborn Eye Inflammation
This open-label, active-controlled phase-3 multicenter trial enrolled 30 pediatric patients with juvenile idiopathic arthritis-associated uv…
A new drug shows early promise for children with stubborn eye inflammation who didn't respond to standard treatments, offering hope when oth…
Apr 18, 2026